Summary

Inadequate chemotherapy, irregularity of treatment and

use of improper antitubercular regimen lead to high

failure rates of antitubercular treatment. As a result, the

prevalence of chronic patients discharging drug-resistant

organisms increases. Alarming figures of drug resistance in

newly detected patients are being reported, mainly from

developing countries. This calls for testing of antibiotic

sensitivity in vitro prior to starting therapy.

Reagent

SENSICULT: LJ Primary/secondary drug panels are

Reagents for laboratory use only. Primary/secondary

drug containing Lowenstein-Jensen media panel for

MTB sensitivity tests is a set of ready to use LowensteinJensen solid medium slants incorporated with individual

antitubercular drugs of recommended specified strength.

Contents

I. Primary drug Lowenstein-Jensen medium panel

contains Lowenstein-Jensen medium with the

following antibiotics/antitubercular drugs.

Drug Symbol pH Concentration

1. lsoniazid IN 7.0+ 0.1 1.0 ng/mL

2. Ethambutol EB 7.0± 0.1 2.0 µg/mL

3. Rifampin RP 7.0± 0.1 4.0 µg/mL

4. Streptomycin ST 7.0 ± 0.1 4.0 µg/mL

5. Pyrazinamide PY 5.5 ± 0.1 100. µg/mL

6. Control for

Pyrazinamide

PC 5.5 ± 0.1

7. LJ Control LJ 7.0 ± 0.1 -

8. Sterile distilled water with glass beads for inoculum preparation

II. Secondary drugs Lowenstein-Jensen media panel

contains Lowenstein-Jensen medium with the

following antibiotics/antitubercular drugs.

Drug Symbol pH Concentration